Published in Women's Health Weekly, October 2nd, 2003
This first clinical trial of UC-781 is a single-center, phase I, placebo-controlled, closed-label, randomized study to evaluate the safety and acceptability of daily intravaginal dosing of the product among 48 healthy sexually abstinent women. Participants will be administering 3.5 ml of 0.1%, 0.25%, 1.0% UC-781...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.